-
公开(公告)号：US20220356459A1
公开(公告)日：2022-11-10
申请号：US17745205
申请日：2022-05-16
Applicant: Da Volterra , Bioaster
Inventor： Jean De Gunzburg , Jean-Denis Docquier
IPC: C12N9/86 , A61K31/407 , A61K31/496 , A61K31/546 , A61K38/50
Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.
-
公开(公告)号：US11365403B2
公开(公告)日：2022-06-21
申请号：US16757968
申请日：2018-10-24
Applicant: Da Volterra , Bioaster
Inventor： Jean De Gunzburg , Jean-Denis Docquier
IPC: C12N9/84 , C12N1/21 , A61K38/50 , C12N9/86 , A61K31/407 , A61K31/496 , A61K31/546 , A61K38/00
Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.
-
公开(公告)号：US11202761B2
公开(公告)日：2021-12-21
申请号：US16046501
申请日：2018-07-26
Applicant: Da Volterra
Inventor： Francois Lescure , Jean De Gunzburg
IPC: A61K9/50 , A61K33/44 , A61K31/731 , A61K31/00 , A61K9/16
Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.
-
公开(公告)号：US20210008096A1
公开(公告)日：2021-01-14
申请号：US17028516
申请日：2020-09-22
Applicant: Da Volterra
Inventor： Jean De Gunzburg , Mark Wilcox , Caroline Chilton
IPC: A61K31/731 , A61K33/44 , A61P31/04
Abstract: The invention relates to the use of an adsorbent to reduce or suppress the pathogenicity or virulence of Clostridium bacteria in vitro, ex vivo or in vivo. The invention may be used in any mammal or environment, and is particularly effective to suppress the pathogenicity or virulence of Clostridium difficile.
-
公开(公告)号：US20200318094A1
公开(公告)日：2020-10-08
申请号：US16757968
申请日：2018-10-24
Applicant: Da Volterra , Bioaster
Inventor： Jean De Gunzburg , Jean-Denis Docquier
IPC: C12N9/86 , A61K38/50 , A61K31/407 , A61K31/496 , A61K31/546
Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.
-
Patent Agency Ranking
公开(公告)号：US20190048331A1
公开(公告)日：2019-02-14
申请号：US16078037
申请日：2017-02-22
Applicant: DA VOLTERRA , BIOASTER
Inventor： Jean DE GUNZBURG , Jean-Denis DOCQUIER
IPC: C12N9/86 , A61K9/00 , A61K38/50 , A61K31/496 , A61K31/546 , A61K31/407
Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.
-
公开(公告)号：US10988749B2
公开(公告)日：2021-04-27
申请号：US16078037
申请日：2017-02-22
Applicant: DA VOLTERRA , BIOASTER
Inventor： Jean De Gunzburg , Jean-Denis Docquier
IPC: C12N9/86 , A61K9/00 , A61K31/407 , A61K31/496 , A61K31/546 , A61K38/50
Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.
-
公开(公告)号：US20190062719A1
公开(公告)日：2019-02-28
申请号：US16078040
申请日：2017-02-22
Applicant: DA VOLTERRA , BIOASTER
Inventor： Jean DE GUNZBURG , Jean-Denis DOCQUIER
Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.
-
公开(公告)号：US20180369156A1
公开(公告)日：2018-12-27
申请号：US16046501
申请日：2018-07-26
Applicant: Da Volterra
Inventor： Francois LESCURE , Jean DE GUNZBURG
IPC: A61K9/50 , A61K33/44 , A61K31/731 , A61K31/00 , A61K9/16
Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.
-
公开(公告)号：US10982205B2
公开(公告)日：2021-04-20
申请号：US16078040
申请日：2017-02-22
Applicant: DA VOLTERRA , BIOASTER
Inventor： Jean De Gunzburg , Jean-Denis Docquier
Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a Verona integron-encoded metallo-β-lactamase (VIM-2) variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.013 seconds)
